Acute Ischemic Heart DiseaseDouble-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: Results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study☆
References (0)
Cited by (74)
Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: A multiple-propensity analysis
2012, Research in Social and Administrative PharmacyCitation Excerpt :Results from some head-to-head trials20,21 and observational studies22-24 suggest that not all ACEIs are equal and clinicians should consider the survival benefit associated with different ACEIs while prescribing to patients with HF.24 However, results from some head-to-head trials,25-27 meta-analysis,12 and observational studies28 suggest a class effect of ACEIs in treatment of HF. There remains a paucity of evidence and conflicting literature on relative effectiveness of different ACEIs in everyday use.
Silent Myocardial Infarction and Long-Term Risk of Heart Failure: The ARIC Study
2018, Journal of the American College of CardiologyCitation Excerpt :Because ECG is a readily available tool with high inter-rater reliability, SMI could be identified with ease as a subclinical risk factor. Although guideline-directed therapy has a clear role in preventing future HF among CMI patients and is therefore part of a quality-of-care core measure (39,40), it is not known whether such benefit exists for persons with SMI. Thus, SMI could be considered as a condition for American College of Cardiology/American Heart Association Stage A HF (i.e., at risk for HF) (41).
Zofenopril: Blood pressure control and cardio-protection
2022, Cardiology JournalTrimetazidine Therapy in Coronary Artery Disease: The Impact on Oxidative Stress, Inflammation, Endothelial Dysfunction, and Long-Term Prognosis
2021, American Journal of TherapeuticsEstablished and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence
2020, Cardiovascular Drugs and TherapyAngiotensin-Converting Enzyme Inhibition: Beyond Blood Pressure Control—The Role of Zofenopril
2020, Advances in Therapy
- ☆
Supported by Menarini Ricerche S.p.A., Firenze, Italy.